Key takeaways
Skyrizi (risankizumab) and Taltz (ixekizumab) are both interleukin antagonists used to treat inflammatory conditions like plaque psoriasis and psoriatic arthritis. However, they differ in several ways. Skyrizi is also approved for Crohn's disease, while Taltz is approved for ankylosing spondylitis and non-radiographic axial spondyloarthritis. Skyrizi is typically administered as an injection every 2 to 3 months after initial doses, whereas Taltz is injected once a month. Skyrizi is available in prefilled syringes, pens, and an On-Body Injector, while Taltz comes as a prefilled syringe and autoinjector. Both medications can increase the risk of infections, but Taltz may also cause flare-ups in people with Crohn's disease or ulcerative colitis. Common side effects for Skyrizi include joint pain and upper respiratory infections, while Taltz often causes injection site reactions and upper respiratory infections. Neither medication has a generic version available.
